Immunocore kondigt de dosering aan van de eerste patiënt met derde ImmTAC® bispecific
IMC-C103C onderzocht in verschillende MAGE-A4 die solide tumoren tot expressie brengen
OXFORDSHIRE, Engeland & CONSHOHOCKEN, Penn. & ROCKVILLE, Md. – (BUSINESS WIRE) – Immunocore Limited, een toonaangevend biotechnologisch bedrijf in T Cell Receptor (TCR), heeft vandaag de start aangekondigd van de eerste klinische proef bij mensen met IMC-C103C het derde bispecifieke, ontwikkeld met behulp van het innovatieve ImmTAC®technology platform van het bedrijf. IMC-C103C is gericht op het bestrijden van tumoren die het eiwit MAGE-A4 (Melanoma-Associated Antigen A4) tot expressie brengen en wordt ontwikkeld in samenwerking met Genentech, een lid van de Roche Group.
De proef (IMC-C103C-101) is bedoeld om de veiligheid en de voorlopige activiteit van IMC-C103C als monotherapie en in combinatie met atezolizumab (Tecentriq®) te bestuderen bij patiënten met MAGE-A4-expressieve kankers.
Immunocore announces dosing of first patient with third ImmTAC® bispecific
IMC-C103C studied in various MAGE-A4 expressing solid tumours
OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md.–(BUSINESS WIRE)– Immunocore Limited, a leading T Cell Receptor (TCR) biotechnology company, today announced the start of the first-in-human clinical trial of IMC-C103C, the third bispecific developed using the company’s innovative ImmTAC® technology platform. IMC-C103C is focused on targeting tumours that express the protein MAGE-A4 (Melanoma-Associated Antigen A4) and is being developed in partnership with Genentech, a member of the Roche Group.
The trial (IMC-C103C-101) is designed to study the safety and preliminary activity of IMC-C103C as a monotherapy and in combination with atezolizumab (Tecentriq®) in patients with MAGE-A4-expressing cancers.
David Berman, Head of Research and Development at Immunocore, commented: “We have now brought our third TCR- engineered bispecific ImmTAC into the clinic. IMC-C103C is designed to re-direct T cells to attack MAGE-A4 expressing tumours and we’re pleased to be moving its clinical development forward in partnership with Genentech.”
– Ends –
About Immunocore
Immunocore, a leading T Cell Receptor (TCR) biotechnology company, is focused on delivering first-in-class biological therapies that have the potential to transform the lives of people with serious diseases. The Company’s primary therapeutic focus is oncology and it also has programs in infectious and autoimmune diseases. Immunocore has a pipeline of proprietary and partnered programs in development and the lead program, tebentafusp (IMCgp100), has entered pivotal clinical studies as a treatment for patients with metastatic uveal melanoma. Collaboration partners include Genentech, GlaxoSmithKline, AstraZeneca, Lilly, and the Bill and Melinda Gates Foundation. Immunocore is headquartered at Milton Park, Oxfordshire, UK, with offices in Conshohocken and Rockville, USA. The Company is privately held by a broad international investor base. For more information, please visit www.immunocore.com.
Tecentriq® (atezolizumab) is a registered trademark of Genentech, a member of the Roche Group.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191208005094/en/
Contacts
Immunocore
Debra Nielsen, Head of Communications
T: +1 (610) 368-8602
E: debra.nielsen@immunocore.com
Follow on Twitter: @Immunocore
Consilium Strategic Communications (corporate and financial)
Mary-Jane Elliott/ Sukaina Virji /Chris Welsh
T: +44 (0)203 709 5700
E: Immunocore@consilium-comms.com
Check out our twitter: @NewsNovumpr